TIMI 64A was a phase 2a randomized, double-blind, placebo-controlled parallel-designed study to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of MEDI5884 in subjects with stable coronary heart disease.
Arterioscler Thromb Vasc Biol. 2021 Dec;41(12):3005-3014.